Nanoviricides, Inc. (NNVC): Cash & Equivalents
$2.79M
As of 2026-06-30
-30.0%
3-year compound annual growth
-32.9%
5-year compound annual growth
-19.4%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $2.79M | +79.3% | 2026-09-28, Balance as of period end |
| 2025-06-30 | $1.56M | -67.5% | 2026-09-28, Balance as of period end |
| 2024-06-30 | $4.80M | -41.1% | 2025-09-29, Balance as of period end |
| 2023-06-30 | $8.15M | -42.1% | 2024-09-27, Balance as of period end |
| 2022-06-30 | $14.07M | -31.4% | 2023-10-13, Balance as of period end |
| 2021-06-30 | $20.52M | +49.7% | 2022-10-13, Balance as of period end |
| 2020-06-30 | $13.71M | +436.5% | 2021-10-12, Balance as of period end |
| 2019-06-30 | $2.56M | -63.9% | 2020-10-13, Balance as of period end |
| 2018-06-30 | $7.08M | -53.1% | 2019-08-23, Balance as of period end |
| 2017-06-30 | $15.10M | -37.5% | 2018-10-12, Balance as of period end |
| 2016-06-30 | $24.16M | -23.2% | 2018-10-12, Balance as of period end |
| 2015-06-30 | $31.47M | -14.2% | 2017-09-28, Balance as of period end |
| 2014-06-30 | $36.70M | +163.6% | 2016-09-16, Balance as of period end |
| 2013-06-30 | $13.92M | -2.5% | 2015-09-14, Balance as of period end |
| 2012-06-30 | $14.27M | +54.8% | 2015-02-23, Balance as of period end |
| 2011-06-30 | $9.22M | +32.6% | 2013-10-08, Balance as of period end |
| 2010-06-30 | $6.96M | n/a | 2013-10-08, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Nanoviricides, Inc. (NNVC) | 2026-06-30 | $2.79M | +79.3% |
| Abbott Laboratories (ABT) | 2025-12-31 | $8.52B | +11.9% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $10.21B | -1.3% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $7.27B | +122.4% |
| Pfizer Inc (PFE) | 2025-12-31 | $1.14B | +9.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $19.71B | -18.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $93.89M | +10.9% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $14.56B | +10.0% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $251.3K | -18.3% |
Compare NNVC, ABT, BMY, LLY side by side · Screen every company in Pharmaceutical Preparations ↗